ArticleLancet (London, England)2021
General population screening for ovarian cancer.
Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of prognostic nutritional index in patients with ovarian cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis.International journal of clinical practice · 2022 · on this mapPooled it
- Super-enhancer-driven ITGB2-AS1 promotes ovarian cancer progression by binding to IQGAP1.Translational oncology · 2026Article
- NOL7 Inhibits Ovarian Cancer Progression and Suppresses Angiogenesis by Stabilizing GADD45A to Deactivate STAT3.Cancer science · 2026Article
- The causal association between psychiatric disorders and gynecological cancer: a bidirectional Mendelian randomization study.Discover oncology · 2025Article
- Utilization of LigasureJournal of clinical medicine · 2025Article
- Intraperitoneal Intraoperative Chemotherapy in Advanced Ovarian Cancer: Rethinking the Future Beyond Complete Macroscopic Resection.Annals of surgical oncology · 2025Article
- Identification of parthanatos-related molecular subtypes and development of prognostic risk models in ovarian cancer based on multi-omics analysis.Journal of ovarian research · 2025Article
- Isolation of exosome-like nanovesicles from Yiqi Huoxue Jiedu decoction and their anti-ovarian cancer activity.Frontiers in pharmacology · 2025Article
- Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer.Frontiers in oncology · 2025Article
- Research Progress of GPR137 in Malignant Tumors: A Review.OncoTargets and therapy · 2025Review
- Acoustic Wave Sensor Detection of an Ovarian Cancer Biomarker with Antifouling Surface Chemistry.Sensors (Basel, Switzerland) · 2024Article
- Interference with MTHFD2 induces ferroptosis in ovarian cancer cells through ERK signaling to suppress tumor malignant progression.Journal of bioenergetics and biomembranes · 2024Article
- Multi-modality deep learning model reaches high prediction accuracy in the diagnosis of ovarian cancer.iScience · 2024Article
- Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.International journal of biological sciences · 2024Article
- Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology.Frontiers in immunology · 2024Review
- Nanoenzymes: A Radiant Hope for the Early Diagnosis and Effective Treatment of Breast and Ovarian Cancers.International journal of nanomedicine · 2024Review
- Emerging roles of circ_NRIP1 in tumor development and cancer therapy (Review).Oncology letters · 2023Review
- Formation of a traditional Chinese medicine self-assembly nanostrategy and its application in cancer: a promising treatment.Chinese medicine · 2023Review
- Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer.Genes & diseases · 2023Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33991478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.